Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT01 in Irritable Bowel Syndrome With Diarrhea
NCT05719896Phase 2Unknown
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asidna in Irritable bowel syndrome with diarrhea (IBS-D) (3 arms). Primary endpoints: Abdominal pain response at 8 weeks, Stool consistency response at 8 weeks and 1 more. Status: unknown.
02
Drugs
asidna
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT05719896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719896.